BBIO in the 13F filings
Bridgebio Pharma Inc · CUSIP 10806X102
- Quarter end
- 30 Jun 2024
- the date the book describes
- Filed
- 14 Aug 2024
- latest of these filings; the earliest 13 Aug 2024
- Managers listing it
- 4
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q1 2024 and Q2 2024; 4 listed it in both
- Shares listed
- 32,595,177
- combined, among listed positions
- Reported value
- $826m
- combined, at the quarter end
Among the 94 comparable managers: 2 buyers (opened or added shares) and 0 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing BBIO in Q2 2024
4 of 4 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Viking Global Investors LP | 25,120,991 | $636m | 2.45% | Held | 0 | 14 Aug 2024 (the filing on sec.gov) |
| Janus Henderson Group Ltd | 4,312,531 | $109m | 0.06% | Added | +999,825 | 14 Aug 2024 (the filing on sec.gov) |
| Capital Research Global Investors | 2,212,085 | $56m | under 0.1% | Held | 0 | 13 Aug 2024 (the filing on sec.gov) |
| Woodline Partners LP | 949,570 | $24m | 0.23% | Added | +248,821 | 14 Aug 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Janus Henderson Group Ltdexisting position · 4,312,531 shares now+999,825
- Woodline Partners LPexisting position · 949,570 shares now+248,821
Reductions
No reduction among listed positions.
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2019 | 2 | $719m | n.a. | n.a. |
| Q3 2019 | 1 | $572m | n.a. | n.a. |
| Q4 2019 | 2 | $1.0bn | n.a. | n.a. |
| Q1 2020 | 3 | $824m | n.a. | n.a. |
| Q2 2020 | 4 | $926m | n.a. | n.a. |
| Q3 2020 | 4 | $1.1bn | n.a. | n.a. |
| Q4 2020 | 5 | $2.0bn | n.a. | n.a. |
| Q1 2021 | 5 | $1.9bn | n.a. | n.a. |
| Q2 2021 | 5 | $1.8bn | n.a. | n.a. |
| Q3 2021 | 4 | $1.4bn | n.a. | n.a. |
| Q4 2021 | 2 | $452m | n.a. | n.a. |
| Q1 2022 | 2 | $276m | n.a. | n.a. |
| Q2 2022 | 2 | $246m | n.a. | n.a. |
| Q3 2022 | 3 | $271m | n.a. | n.a. |
| Q4 2022 | 2 | $204m | n.a. | n.a. |
| Q1 2023 | 4 | $477m | n.a. | n.a. |
| Q2 2023 | 2 | $463m | n.a. | n.a. |
| Q3 2023 | 9 | $898m | n.a. | n.a. |
| Q4 2023 | 9 | $1.3bn | 1 | 7 |
| Q1 2024 | 7 | $1.1bn | 5 | 2 |
| Q2 2024 | 4 | $826m | 2 | 0 |
| Q3 2024 | 8 | $927m | 7 | 0 |
| Q4 2024 | 7 | $1.2bn | 4 | 3 |
| Q1 2025 | 9 | $1.6bn | 6 | 3 |
| Q2 2025 | 15 | $2.3bn | 11 | 4 |
| Q3 2025 | 14 | $2.3bn | 5 | 9 |
| Q4 2025 | 18 | $4.3bn | 22 | 12 |
| Q1 2026 | 20 | $4.4bn | 20 | 14 |
| Q2 2026 | 18 | $4.5bn | 24 | 15 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
BBIO and LLY →BBIO and JNJ →BBIO and VRTX →Choose a stock to compare with BBIO →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own BBIO, latest filings →Back to the 13F Explorer →